Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae

被引:89
|
作者
Kang, CI
Kim, SH
Kim, DM
Park, WB
Lee, KD
Kim, HB
Oh, MD
Min, EC
Choe, KW
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Res Inst, Seoul, South Korea
来源
关键词
D O I
10.1086/502310
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To evaluate risk factors and treatment outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KP). DESIGN: Retrospective case-control study. Stored blood isolates of K pneumoniae were tested for ESBL production by NCCLS guidelines, double-disk synergy test, or both. SETTING: A 1,500-bed, tertiary-care university hospital and referral center. PATIENTS: Sixty case-patients with bacteremia due to ESBL-KP were compared with 60 matched control-patients with non-ESBL-KP. RESULTS: There were no significant differences in age, gender, APACHE 11 score, or underlying diseases between the groups. Independent risk factors for infections caused by ESBL-KP were urinary catheterization, invasive procedure within the previous 72 hours, and an increasing number of antibiotics administered within the previous 30 days. Complete response rate, evaluated 72 hours after initial antimicrobial therapy, was higher among control-patients (13.3% vs 36.7%; P =.003). Treatment failure rate was higher among case-patients (35.0% vs 15%; P =.011). Overall 30-day mortality rate was 30% for case-patients and 28.3% for control-patients (P =.841). Case-patients who received imipenem or ciprofloxacin as a definitive antibiotic had 10.5% mortality. The mortality rate for initially ineffective therapy was no higher than that for initially effective therapy (9.1% vs 11.1%; P =1.000), but statistical power was low for evaluating mortality in the absence of septic shock. CONCLUSION: For K pneumoniae bacteremia, patients with ESBL-KP had a higher initial treatment failure rate but did not have higher mortality if antimicrobial therapy was appropriately adjusted in this study with limited statistical power.
引用
收藏
页码:860 / 867
页数:8
相关论文
共 50 条
  • [21] Nosocomial endocarditis due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a child
    Shipton, SE
    Cotton, MF
    Wessels, G
    Wasserman, E
    [J]. SOUTH AFRICAN MEDICAL JOURNAL, 2001, 91 (04): : 321 - 322
  • [22] Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli
    Bishara, J
    Livne, G
    Ashkenazi, S
    Levy, I
    Pitlik, S
    Ofir, O
    Lev, B
    Samra, Z
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2005, 7 (05): : 298 - 301
  • [23] Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae A case-control study
    Mosqueda-Gomez, Juan L.
    Montano-Loza, Aldo
    Rolon, Ana L.
    Cervantes, Carlos
    Bobadilla-del-Valle, J. Miriam
    Silva-Sanchez, Jesus
    Garza-Ramos, Ulises
    Villasis-Keevera, Angelina
    Galindo-Fraga, Arturo
    Palacios, Guillermo M. Ruiz
    Ponce-de-Leon, Alfredo
    Sifuentes-Osornio, Jose
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (06) : 653 - 659
  • [24] Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae:: Risk factors, molecular epidemiology, and clinical outcome
    Tumbarello, M
    Spanu, T
    Sanguinetti, M
    Citton, R
    Montuori, E
    Leone, F
    Fadda, G
    Cauda, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) : 498 - 504
  • [25] The clinical impact of sputum isolation of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
    Shikata, Maki
    Iwanaga, Naoki
    Nagayoshi, Yosuke
    Takemoto, Shinnosuke
    Oono, Tadayoshi
    Hisatomi, Keiko
    Nagashima, Seiji
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S209 - S209
  • [26] Risk factors for acquisition of extended-spectrum beta-lactamase producing Klebsiella infections
    Palanduz, A
    Yalçin, I
    Kaygusuz, A
    Güler, N
    Salman, N
    Önes, Ü
    Somer, A
    Töreci, K
    [J]. MEDICAL SCIENCE RESEARCH, 1999, 27 (06): : 407 - 408
  • [27] Risk Factors and Outcomes with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Bloodstream Infections among Solid Organ Transplant Recipients.
    Anesi, J.
    Blumberg, E.
    Lautenbach, E.
    Tamma, P.
    Thom, K.
    Alby, K.
    Bilker, W.
    Omorogbe, J.
    Tolomeo, P.
    Werzen, A.
    Nemati, K.
    Han, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 359 - 359
  • [28] Impact of cephalosporin restriction on incidence of infections with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in an endemic setting
    Nadrah, Kristina
    Pirs, Mateja
    Kreft, Samo
    Premru, Manica Mueller
    Beovic, Bojana
    [J]. JOURNAL OF CHEMOTHERAPY, 2018, 30 (03) : 150 - 156
  • [29] Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
    Kang, CI
    Kim, SH
    Kim, DM
    Park, WB
    Lee, KD
    Kim, HB
    Oh, MD
    Kim, EC
    Choe, KW
    [J]. MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 2004, 10 (01): : 71 - 76
  • [30] Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum β-lactamase Klebsiella pneumoniae among cancer patients
    Li, D.
    Chen, Y.
    Zhang, W.
    Zheng, S.
    Zhang, Q.
    Bai, C.
    Zhang, P.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 (03) : 463 - 469